Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CBX7 | O95931 | 2/20 | 0.42 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314930 | 0.83 | RAB9A (0.53) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL31389174 | 0.81 | RAB9A (0.58) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL24281120 | 0.78 | RAB9A (0.49) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL15314952 | 0.78 | GAA (0.55) | RAB9ASMN1; SMN2MAPTKDM4EHTT | |
| SCHEMBL15314985 | 0.78 | TSHR (0.47) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL29083889 | 0.76 | MAPT (0.58) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL24281266 | 0.76 | SMN1; SMN2 (0.47) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL25890238 | 0.75 | RAD52 (0.55) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL31389179 | 0.75 | RAB9A (0.49) | RAB9ASMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL28759307 | 0.75 | TP53 (0.65) | RAB9ASMN1; SMN2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20120101236-A1 | POLYIMIDE PRECURSOR COMPOSITION CONTAINING POLYAMIC ACID ALKYL ESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | RAB9A 1231/4885SMN1; SMN2 393/4885MAPT 2596/4885 |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | RAB9A 1231/4885SMN1; SMN2 393/4885MAPT 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.